Table 1 Baseline characteristics of enrolled patients
Parameter | Value |
|---|---|
Sex (M) (%) | 108 (63.2) |
Age (yr) (mean ± SD) | 57.72 ± 7.95 |
Tobacco Consumers (yes) (%) | 98 (57.3) |
Cirrhosis (yes) (%) | 171 (100) |
DM (yes) (%) | 52 (30.4) |
Mode of HCC Diagnosis | |
Symptomatic (%) | 146 (85.4) |
Incidental (%) | 16 (9.4) |
Screening (%) | 9 (5.2) |
TH Patients (%) | 51 (29.8) |
INF-α based treatment (with or without Ribavirin) (%) | 19 (37.3) |
DAA based treatment (%) | 32 (62.7) |
Duration between HCV treatment and HCC diagnosis (months) (mean ± SD) | 34.55 ± 30.13 |
Duration between treatment with IFN and HCC (months) (mean ± SD) | 70.74 ± 15.03 |
Duration between treatment with DAA and HCC (months) (mean ± SD) | 13.05 ± 7.35 |
AgI score of HCV Treatment Naïve Group (median, range) | 6.0 (4–12) |
AgI score of HCV Treatment Group (median, range) | 8.0 (4–11) |